Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

NCT05580991 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-02-13

No results posted yet for this study

Summary

To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.

Conditions

Interventions

DRUG

CAN1012

CAN1012 IT injection (once every 4 weeks)

Sponsors & Collaborators

  • Canwell Biotech Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-09
Primary Completion
2025-06-30
Completion
2025-06-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05580991 on ClinicalTrials.gov